Home
Search:
1146 feeds
357 categories
0 articles (<24 hours)
35 registered users

Use the Mobile version
Mobile

Follow our Twitter feed

View our Linkpartners
Links

Username:
Password:

Register | Retrieve

General


RSS FeedsPhase II data showed Roche´s investigational polatuzumab vedotin plus bendamustine and MabThera/Rituxan (BR) increased complete response rates compared to BR alone in previously treated aggressive lymphoma
(WorldNews Switzerland)

 
 

10 december 2017 16:15:04

 
Phase II data showed Roche´s investigational polatuzumab vedotin plus bendamustine and MabThera/Rituxan (BR) increased complete response rates compared to BR alone in previously treated aggressive lymphoma
(WorldNews Switzerland)
 


Basel, 10 December 2017 Phase II data showed Roche`s investigational polatuzumab vedotin plus bendamustine and MabThera/Rituxan (BR) increased complete response rates compared to BR alone in previously treated aggressive lymphoma Polatuzumab vedotin combination demonstrated improvements across multiple efficacy measures compared to BR alone in relapsed or refractory diffuse large B-cell lymphoma These data led to FDA Breakthrough Therapy and EMA PRIME (PRIority MEdicines) designations Results will be presented at the 59th American Society of Hematology Annual Meeting Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive results from the randomised phase II GO29365 study that compared...


 
10 viewsCategory: General > Europe > Switzerland
 
CRISPR Therapeutics Announces Oral Presentation of New Data on CTX001, a CRISPR Gene-Edited Therapy for
(WorldNews Switzerland)
Associate Director of Regulatory Affairs
(WorldNews Switzerland)
 
 
blog comments powered by Disqus


Copyright © 2008 - 2024 Indigonet Services B.V.. Contact: Tim Hulsen. Read here our privacy notice.
Other websites of Indigonet Services B.V.: Nieuws Vacatures Science Tweets Nachrichten